CNS Pharmaceuticals, Inc. (CNSP)
NASDAQ: CNSP · Real-Time Price · USD
0.8370
+0.0370 (4.62%)
At close: Jun 26, 2025, 4:00 PM
0.8398
+0.0028 (0.33%)
After-hours: Jun 26, 2025, 7:30 PM EDT
CNS Pharmaceuticals Employees
As of December 31, 2024, CNS Pharmaceuticals had 5 total employees, including 3 full-time and 2 part-time employees. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$3,122,875
Market Cap
4.57M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
CNSP News
- 2 days ago - CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287 - Accesswire
- 21 days ago - CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit - Accesswire
- 5 weeks ago - CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update - Accesswire
- 6 weeks ago - CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - Accesswire
- 6 weeks ago - CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287 - Accesswire
- 3 months ago - CNS Pharmaceuticals Reports Full Year 2024 Financial Results - Accesswire
- 3 months ago - CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects - Benzinga
- 3 months ago - CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme - Accesswire